RGS10 and acute myeloid leukemia: Gene expression profiling in AML is a well-established way to provide valuable diagnostic insight into predicting clinical outcome and our data show that the expression of FAM26F and RGS10, which are significantly enriched in two AML subtypes, correlates with significantly poorer clinical outcome.